Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors

Trial Profile

Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2017 Primary endpoint (Nocturnal parameters from wearable sensors during nighttime) has been met, according to the results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 03 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top